Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2021 · 10-Q
Revenue$9.83M$9.83M+8.5% vs Q1 2020 Net Income-$4.21M-$4.21MN/M vs Q1 2020 EPS Diluted-$1.03-$1.03N/M vs Q1 2020 Gross Profit$4,517,000+53.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$5,006,000N/M Margins · derivedGross margin45.9%+13.4 pt vs Q1 2020
Operating margin-38.8%+31.3 pt vs Q1 2020
Net margin-42.8%+28.9 pt vs Q1 2020
ended Mar 31, 2021 · filed May 11, 2021 · 41 d after period end